DocDollars

Rigel Pharmaceuticals, Inc.

CA · United States · Reporting entity ID 100000226808

Total reported 2019–2025
$19.8M
#319 of 2,960 reporting companies — 0% of all reported industry payments
$7.97M in general payments across 30,911 records, plus $11.9M in research funding across 552 records.

How it breaks down

General payments $7,965,916
Research funding $11,882,684

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Rigel Pharmaceuticals, Inc. reported $19.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #319 of 2,960 reporting companies. 60% of that was research funding and 40% general payments such as consulting, speaking, food and travel. 30,911 general payment records and 552 research records were filed.

Common questions about Rigel Pharmaceuticals, Inc.

How much has Rigel Pharmaceuticals, Inc. paid US doctors?

Rigel Pharmaceuticals, Inc. reported $19,848,600 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,965,916 in general payments, $11,882,684 in research funding.

How does Rigel Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #319 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Rigel Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.